OPKO Health (OPK) Competitors

$1.08 -0.02 (-1.36%)

As of 01:15 PM Eastern

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy OPKO Health stock or one of its competitors? MarketBeat compares OPKO Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OPKO Health include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does OPKO Health compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Celldex Therapeutics presently has a consensus price target of $49.78, suggesting a potential upside of 57.82%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 42.86%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Celldex Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

OPKO Health has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,607.52	-$258.76M	-$4.26	N/A
OPKO Health	$606.90M	1.35	-$225.68M	-$0.27	N/A

64.6% of OPKO Health shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Celldex Therapeutics had 5 more articles in the media than OPKO Health. MarketBeat recorded 12 mentions for Celldex Therapeutics and 7 mentions for OPKO Health. Celldex Therapeutics' average media sentiment score of 0.88 beat OPKO Health's score of 0.61 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
OPKO Health	-36.63%	-16.78%	-10.98%

Summary

OPKO Health beats Celldex Therapeutics on 9 of the 16 factors compared between the two stocks.

How does OPKO Health compare to BioCryst Pharmaceuticals?

OPKO Health (NASDAQ:OPK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than OPKO Health. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.35	-$225.68M	-$0.27	N/A
BioCryst Pharmaceuticals	$874.84M	2.66	$263.86M	-$1.78	N/A

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

OPKO Health currently has a consensus price target of $1.55, suggesting a potential upside of 42.86%. BioCryst Pharmaceuticals has a consensus price target of $20.70, suggesting a potential upside of 126.11%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

OPKO Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than OPKO Health. MarketBeat recorded 13 mentions for BioCryst Pharmaceuticals and 7 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.61 beat BioCryst Pharmaceuticals' score of 0.27 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

OPKO Health has a net margin of -36.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. OPKO Health's return on equity of -16.78% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

BioCryst Pharmaceuticals beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Innoviva?

Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 63.11%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 42.86%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Innoviva is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
OPKO Health	-36.63%	-16.78%	-10.98%

Innoviva has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69
OPKO Health	$606.90M	1.35	-$225.68M	-$0.27	N/A

In the previous week, OPKO Health had 2 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for OPKO Health and 5 mentions for Innoviva. Innoviva's average media sentiment score of 0.82 beat OPKO Health's score of 0.61 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats OPKO Health on 12 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Novavax?

OPKO Health (NASDAQ:OPK) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Novavax had 12 more articles in the media than OPKO Health. MarketBeat recorded 19 mentions for Novavax and 7 mentions for OPKO Health. Novavax's average media sentiment score of 0.76 beat OPKO Health's score of 0.61 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.35	-$225.68M	-$0.27	N/A
Novavax	$1.12B	1.36	$440.30M	-$0.58	N/A

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Novavax	-14.73%	-14.82%	1.23%

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 42.86%. Novavax has a consensus target price of $12.13, indicating a potential upside of 30.87%. Given OPKO Health's stronger consensus rating and higher probable upside, equities analysts plainly believe OPKO Health is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Summary

Novavax beats OPKO Health on 10 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Zenas BioPharma?

OPKO Health (NASDAQ:OPK) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Zenas BioPharma has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Zenas BioPharma	N/A	-112.13%	-76.14%

In the previous week, Zenas BioPharma had 2 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for Zenas BioPharma and 7 mentions for OPKO Health. Zenas BioPharma's average media sentiment score of 1.05 beat OPKO Health's score of 0.61 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 42.86%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 145.62%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

OPKO Health has higher revenue and earnings than Zenas BioPharma. OPKO Health is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.35	-$225.68M	-$0.27	N/A
Zenas BioPharma	$10M	103.44	-$377.74M	-$7.81	N/A

OPKO Health has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, indicating that its share price is 161% less volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

OPKO Health beats Zenas BioPharma on 9 of the 17 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPK vs. The Competition

Export

Metric	OPKO Health	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$819.27M	$6.72B	$6.24B	$12.30B
Dividend Yield	N/A	1.74%	2.80%	5.35%
P/E Ratio	-4.02	49.25	20.39	25.31
Price / Sales	1.35	66.71	541.96	72.69
Price / Cash	N/A	24.26	43.26	56.33
Price / Book	0.68	6.46	9.79	6.90
Net Income	-$225.68M	$158.34M	$3.56B	$333.98M
7 Day Performance	-4.82%	-2.81%	0.43%	-0.27%
1 Month Performance	-8.05%	-4.75%	-0.87%	1.56%
1 Year Performance	-18.42%	-3.53%	35.95%	32.45%

OPKO Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPK OPKO Health	2.7525 of 5 stars	$1.09 -1.4%	$1.55 +42.9%	-12.7%	$819.27M	$606.90M	N/A	1,373
CLDX Celldex Therapeutics	3.1887 of 5 stars	$32.28 -5.0%	$48.00 +48.7%	+71.3%	$2.67B	$1.54M	N/A	150	Analyst Forecast Analyst Revision
BCRX BioCryst Pharmaceuticals	3.7493 of 5 stars	$8.58 -0.5%	$20.70 +141.3%	-2.8%	$2.19B	$874.84M	N/A	530
INVA Innoviva	4.1108 of 5 stars	$22.52 -1.6%	$36.20 +60.7%	+26.9%	$1.70B	$411.33M	3.75	100	Positive News
NVAX Novavax	2.1198 of 5 stars	$9.50 -6.0%	$12.13 +27.6%	+56.9%	$1.66B	$1.12B	N/A	1,990	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPK) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does OPKO Health compare to Celldex Therapeutics?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Summary

How does OPKO Health compare to Innoviva?

Summary

How does OPKO Health compare to Novavax?

Summary

How does OPKO Health compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does OPKO Health compare to Celldex Therapeutics?

Do analysts prefer CLDX or OPK?

Which has more risk & volatility, CLDX or OPK?

Which has stronger earnings & valuation, CLDX or OPK?

Do insiders & institutionals hold more shares of CLDX or OPK?

Does the media prefer CLDX or OPK?

Is CLDX or OPK more profitable?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Which has preferable earnings & valuation, OPK or BCRX?

Do institutionals & insiders hold more shares of OPK or BCRX?

Do analysts recommend OPK or BCRX?

Which has more volatility & risk, OPK or BCRX?

Does the media favor OPK or BCRX?

Is OPK or BCRX more profitable?

Summary

How does OPKO Health compare to Innoviva?

Do analysts rate INVA or OPK?

Do insiders & institutionals believe in INVA or OPK?

Is INVA or OPK more profitable?

Which has more volatility and risk, INVA or OPK?

Which has preferable valuation & earnings, INVA or OPK?

Does the media prefer INVA or OPK?

Summary

How does OPKO Health compare to Novavax?

Does the media favor OPK or NVAX?

Which has more risk & volatility, OPK or NVAX?

Do insiders and institutionals believe in OPK or NVAX?

Which has stronger earnings and valuation, OPK or NVAX?

Is OPK or NVAX more profitable?

Do analysts recommend OPK or NVAX?

Summary

How does OPKO Health compare to Zenas BioPharma?

Is OPK or ZBIO more profitable?

Does the media favor OPK or ZBIO?

Do analysts recommend OPK or ZBIO?

Which has stronger earnings & valuation, OPK or ZBIO?

Which has more risk & volatility, OPK or ZBIO?

Do institutionals and insiders have more ownership in OPK or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools